Neurophet's AI-Powered AQUA Software Receives FDA Clearance for Advanced Multiple Sclerosis Analysis
time to read: 0152. In a significant step forward for both artificial intelligence and neurology, Neurophet, a company dedicated to advancing brain disease diagnosis and treatment, recently announced that its cutting-edge software, Neurophet AQUA, has received 510(k) clearance from the U.S. FDA. This milestone comes as the software introduces an innovative feature for analyzing multiple sclerosis (MS), a chronic and often debilitating condition of the central nervous system.
Source: PR NewsWire
Feature
Text
FDA Approves Flyrcado™: A Game-Changer in PET Imaging for Coronary Artery Disease Diagnosis
Time to read: 01:15 GE HealthCare has secured FDA approval for Flyrcado™ (flurpiridaz F 18), the first-ever PET myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD).
Source: GE Press Release
Text
